>

Rethinking obesity care in Disorders of Gut-Brain Interaction

February 19, 2026

.

1

mins to read

Written by

Christina Sexton

GLP-1 receptor agonists are rapidly reshaping obesity treatment and are increasingly used in patients with disorders of the brain-gut interaction (DGBIs). Yet their gastrointestinal effects don’t always align with standard weight-loss pathways.

Watch the discussion led by gastroenteerologist Dr. Samuel Muench for practical guideance on managing these complex patients.

Contents

Fax: 212-377-0271

Nerva’s data is securely managed in compliance with SOC-2 standards

*Disclaimer: Nerva is a self-guided program that may help people self-manage and live well with their diagnosed irritable bowel syndrome or other disorder of gut-brain interaction (DGBI) and associated anxiety & depression symptoms. Nerva has not been evaluated by the FDA, TGA, MHRA or similar regulatory bodies. Users are directed to not make any changes to their prescribed medication or other type of medical treatment without seeking professional medical advice. Some in-app coaching content may be generated by an AI system for educational and wellness purposes only and does not replace professional medical care, diagnosis, or treatment.